Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.

Vasmatzis G, Wang X, Smadbeck JB, Murphy SJ, Geiersbach KB, Johnson SH, Gaitatzes AG, Asmann YW, Kosari F, Borad MJ, Serie DJ, McLaughlin SA, Kachergus JM, Necela BM, Thompson EA.

BMC Cancer. 2018 Jul 13;18(1):738. doi: 10.1186/s12885-018-4594-0.

2.

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.

Necela BM, Axenfeld BC, Serie DJ, Kachergus JM, Perez EA, Thompson EA, Norton N.

Clin Transl Med. 2017 Dec;6(1):5. doi: 10.1186/s40169-016-0133-2. Epub 2017 Jan 18.

3.

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.

Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA.

J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw207. Print 2017 Feb.

4.

Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.

Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, Kachergus JM, Feathers RW, Carr JM, Crook JE, Moreno-Aspitia A, Anastasiadis PZ, Perez EA, Thompson EA.

PLoS One. 2016 Apr 14;11(4):e0153411. doi: 10.1371/journal.pone.0153411. eCollection 2016.

5.

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Apr 30;10(4):e0127133. doi: 10.1371/journal.pone.0127133. eCollection 2015. No abstract available.

6.

Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Mar 27;10(3):e0122209. doi: 10.1371/journal.pone.0122209. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127133. Aspita, Alvaro Moreno [corrected to Moreno-Aspitia, Alvaro].

7.

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

Kasaian K, Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, Schein JE, Rivera M, Necela BM, Kachergus JM, Casler JD, Mungall AJ, Moore RA, Marra MA, Copland JA, Thompson EA, Smallridge RC, Jones SJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):E611-5. doi: 10.1210/jc.2014-3622. Epub 2015 Jan 27.

8.

The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.

Tang X, Baheti S, Shameer K, Thompson KJ, Wills Q, Niu N, Holcomb IN, Boutet SC, Ramakrishnan R, Kachergus JM, Kocher JP, Weinshilboum RM, Wang L, Thompson EA, Kalari KR.

Nucleic Acids Res. 2014 Dec 16;42(22):e172. doi: 10.1093/nar/gku1005. Epub 2014 Oct 28.

9.

Clinical and molecular features of Hürthle cell carcinoma of the thyroid.

Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, Necela BM, Hay ID, Westphal SA, Grant CS, Thompson GB, Schlinkert RT, Thompson EA, Smallridge RC.

J Clin Endocrinol Metab. 2015 Jan;100(1):55-62. doi: 10.1210/jc.2014-1634.

PMID:
25259908
10.

EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population.

Nishioka K, Funayama M, Vilariño-Güell C, Ogaki K, Li Y, Sasaki R, Kokubo Y, Kuzuhara S, Kachergus JM, Cobb SA, Takahashi H, Mizuno Y, Farrer MJ, Ross OA, Hattori N.

Parkinsonism Relat Disord. 2014 Jun;20(6):659-61. doi: 10.1016/j.parkreldis.2014.03.004. Epub 2014 Mar 18.

11.

Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors.

Norton N, Sun Z, Asmann YW, Serie DJ, Necela BM, Bhagwate A, Jen J, Eckloff BW, Kalari KR, Thompson KJ, Carr JM, Kachergus JM, Geiger XJ, Perez EA, Thompson EA.

PLoS One. 2013 Nov 22;8(11):e81925. doi: 10.1371/journal.pone.0081925. eCollection 2013.

12.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

13.

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations.

Kalari KR, Rossell D, Necela BM, Asmann YW, Nair A, Baheti S, Kachergus JM, Younkin CS, Baker T, Carr JM, Tang X, Walsh MP, Chai HS, Sun Z, Hart SN, Leontovich AA, Hossain A, Kocher JP, Perez EA, Reisman DN, Fields AP, Thompson EA.

Front Oncol. 2012 Feb 10;2:12. doi: 10.3389/fonc.2012.00012. eCollection 2012.

14.

First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Puschmann A, Englund E, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Törnqvist AL, Rehncrona S, Widner H, Wszolek ZK, Farrer MJ, Nilsson C.

Parkinsonism Relat Disord. 2012 May;18(4):332-8. doi: 10.1016/j.parkreldis.2011.11.019. Epub 2011 Dec 6.

15.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

16.

VPS35 mutations in Parkinson disease.

Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ.

Am J Hum Genet. 2011 Jul 15;89(1):162-7. doi: 10.1016/j.ajhg.2011.06.001. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):347.

17.

Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease.

Nishioka K, Vilariño-Güell C, Cobb SA, Kachergus JM, Ross OA, Hentati E, Hentati F, Farrer MJ.

Parkinsonism Relat Disord. 2010 Dec;16(10):686-7. doi: 10.1016/j.parkreldis.2010.09.007. Epub 2010 Oct 23.

18.

Glucocerebrosidase mutations in diffuse Lewy body disease.

Nishioka K, Ross OA, Vilariño-Güell C, Cobb SA, Kachergus JM, Mann DM, Snowden J, Richardson AM, Neary D, Robinson CA, Rajput A, Papapetropoulos S, Mash DC, Pahwa R, Lyons KE, Wszolek ZK, Dickson DW, Farrer MJ.

Parkinsonism Relat Disord. 2011 Jan;17(1):55-7. doi: 10.1016/j.parkreldis.2010.09.009.

19.

Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa.

Jasinska-Myga B, Kachergus J, Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Kefi M, Middleton LT, Ishihara-Paul L, Gibson RA, Amouri R, Yahmed SB, Sassi SB, Zouari M, El Euch G, Ross OA, Hentati F, Farrer MJ.

Mov Disord. 2010 Oct 15;25(13):2052-8. doi: 10.1002/mds.23283.

PMID:
20721913
20.

Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease.

Nishioka K, Wider C, Vilariño-Güell C, Soto-Ortolaza AI, Lincoln SJ, Kachergus JM, Jasinska-Myga B, Ross OA, Rajput A, Robinson CA, Ferman TJ, Wszolek ZK, Dickson DW, Farrer MJ.

Arch Neurol. 2010 Aug;67(8):970-5. doi: 10.1001/archneurol.2010.177.

21.

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, Nutt JG, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wider C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ.

Mov Disord. 2010 Oct 15;25(13):2156-63. doi: 10.1002/mds.23265.

22.

LRRK2 variation and Parkinson's disease in African Americans.

Ross OA, Wilhoite GJ, Bacon JA, Soto-Ortolaza A, Kachergus J, Cobb SA, Puschmann A, Vilariño-Güell C, Farrer MJ, Graff-Radford N, Meschia JF, Wszolek ZK.

Mov Disord. 2010 Sep 15;25(12):1973-6. doi: 10.1002/mds.23163.

23.

LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease.

Vilariño-Güell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA, Soto-Ortolaza AI, Behrouz B, Heckman MG, Diehl NN, Testa CM, Wszolek ZK, Uitti RJ, Jankovic J, Louis ED, Clark LN, Rajput A, Farrer MJ.

Neurogenetics. 2010 Oct;11(4):401-8. doi: 10.1007/s10048-010-0241-x. Epub 2010 Apr 6.

24.

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Dachsel JC, Nishioka K, Vilariño-Güell C, Lincoln SJ, Soto-Ortolaza AI, Kachergus J, Hinkle KM, Heckman MG, Jasinska-Myga B, Taylor JP, Dickson DW, Gibson RA, Hentati F, Ross OA, Farrer MJ.

Mech Ageing Dev. 2010 Mar;131(3):210-4. doi: 10.1016/j.mad.2010.01.009. Epub 2010 Feb 6.

25.

Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa.

Nishioka K, Vilariño-Güell C, Cobb SA, Kachergus JM, Ross OA, Wider C, Gibson RA, Hentati F, Farrer MJ.

Neurosci Lett. 2010 Jun 21;477(2):57-60. doi: 10.1016/j.neulet.2009.11.066. Epub 2009 Nov 27.

26.

LINGO1 rs9652490 is associated with essential tremor and Parkinson disease.

Vilariño-Güell C, Ross OA, Wider C, Jasinska-Myga B, Cobb SA, Soto-Ortolaza AI, Kachergus JM, Keeling BH, Dachsel JC, Melrose HL, Behrouz B, Wszolek ZK, Uitti RJ, Aasly JO, Rajput A, Farrer MJ.

Parkinsonism Relat Disord. 2010 Feb;16(2):109-11. doi: 10.1016/j.parkreldis.2009.08.006. Epub 2009 Aug 31.

27.

A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hägerström D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C.

Parkinsonism Relat Disord. 2009 Nov;15(9):627-32. doi: 10.1016/j.parkreldis.2009.06.007. Epub 2009 Jul 25.

28.

Expanding the clinical phenotype of SNCA duplication carriers.

Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, Kono S, Obi T, Mizoguchi K, Inoue Y, Imai H, Takanashi M, Mizuno Y, Farrer MJ, Hattori N.

Mov Disord. 2009 Sep 15;24(12):1811-9. doi: 10.1002/mds.22682.

PMID:
19562770
29.

Characterization of DCTN1 genetic variability in neurodegeneration.

Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destée A, Krygowska-Wajs A, Chartier-Harlin MC, Ross OA, Rademakers R, Farrer MJ.

Neurology. 2009 Jun 9;72(23):2024-8. doi: 10.1212/WNL.0b013e3181a92c4c.

30.

DCTN1 mutations in Perry syndrome.

Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilariño-Güell C, Ross OA, Brown LA, Castanedes-Casey M, Dickson DW, Wszolek ZK.

Nat Genet. 2009 Feb;41(2):163-5. doi: 10.1038/ng.293. Epub 2009 Jan 11.

31.

Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.

Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis H, Plaitakis A, Ferreira JJ, Sampaio C, Bonifati V, Wu RM, Zabetian CP, Farrer MJ.

Parkinsonism Relat Disord. 2009 Jul;15(6):466-7. doi: 10.1016/j.parkreldis.2008.09.001. Epub 2008 Oct 26.

32.

Fine-mapping and candidate gene investigation within the PARK10 locus.

Haugarvoll K, Toft M, Skipper L, Heckman MG, Crook JE, Soto A, Ross OA, Hulihan MM, Kachergus JM, Sando SB, White LR, Lynch T, Gibson JM, Uitti RJ, Wszolek ZK, Aasly JO, Farrer MJ.

Eur J Hum Genet. 2009 Mar;17(3):336-43. doi: 10.1038/ejhg.2008.187. Epub 2008 Oct 15.

33.

Glucosidase-beta variations and Lewy body disorders.

Farrer MJ, Williams LN, Algom AA, Kachergus J, Hulihan MM, Ross OA, Rajput A, Papapetropoulos S, Mash DC, Dickson DW.

Parkinsonism Relat Disord. 2009 Jul;15(6):414-6. doi: 10.1016/j.parkreldis.2008.08.004. Epub 2008 Oct 1.

34.

Pallidonigral TDP-43 pathology in Perry syndrome.

Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, Lechevalier B, Calne DB, Personett DA, Hulihan M, Kachergus J, Rademakers R, Baker MC, Grantier LL, Sujith OK, Brown L, Calne S, Farrer MJ, Wszolek ZK.

Parkinsonism Relat Disord. 2009 May;15(4):281-6. doi: 10.1016/j.parkreldis.2008.07.005. Epub 2008 Aug 23.

35.

PINK1 mutations and parkinsonism.

Ishihara-Paul L, Hulihan MM, Kachergus J, Upmanyu R, Warren L, Amouri R, Elango R, Prinjha RK, Soto A, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Neurology. 2008 Sep 16;71(12):896-902. doi: 10.1212/01.wnl.0000323812.40708.1f. Epub 2008 Aug 6.

36.

Genomic investigation of alpha-synuclein multiplication and parkinsonism.

Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ.

Ann Neurol. 2008 Jun;63(6):743-50. doi: 10.1002/ana.21380.

37.

LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.

Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Lancet Neurol. 2008 Jul;7(7):591-4. doi: 10.1016/S1474-4422(08)70116-9. Epub 2008 Jun 6. Erratum in: Lancet Neurol. 2008 Aug;7(8):675.

PMID:
18539535
38.

Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.

Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ.

Acta Neurol Scand. 2008 Nov;118(5):320-7. doi: 10.1111/j.1600-0404.2008.01019.x. Epub 2008 May 15.

PMID:
18485051
39.

Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK.

Neurology. 2008 Apr 15;70(16 Pt 2):1456-60. doi: 10.1212/01.wnl.0000304044.22253.03. Epub 2008 Mar 12.

40.

Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5.

Wider C, Melquist S, Hauf M, Solida A, Cobb SA, Kachergus JM, Gass J, Coon KD, Baker M, Cannon A, Stephan DA, Schorderet DF, Ghika J, Burkhard PR, Kapatos G, Hutton M, Farrer MJ, Wszolek ZK, Vingerhoets FJ.

Neurology. 2008 Apr 15;70(16 Pt 2):1377-83. Epub 2007 Sep 5.

41.

Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.

Perez-Pastene C, Cobb SA, Díaz-Grez F, Hulihan MM, Miranda M, Venegas P, Godoy OT, Kachergus JM, Ross OA, Layson L, Farrer MJ, Segura-Aguilar J.

Neurosci Lett. 2007 Jul 18;422(3):193-7. Epub 2007 Jun 17.

42.

Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schüle B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ.

Neurology. 2007 Mar 20;68(12):916-22. Epub 2007 Jan 24.

PMID:
17251522
43.

Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ.

Neurogenetics. 2007 Apr;8(2):95-102. Epub 2007 Jan 16.

PMID:
17225181
44.

Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.

Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ.

Mov Disord. 2007 Feb 15;22(3):389-92.

PMID:
17216639
45.

Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Dächsel JC, Ross OA, Mata IF, Kachergus J, Toft M, Cannon A, Baker M, Adamson J, Hutton M, Dickson DW, Farrer MJ.

Acta Neuropathol. 2007 May;113(5):601-6. Epub 2006 Dec 7.

PMID:
17151837
46.

LRRK2 mutations are a common cause of Parkinson's disease in Spain.

Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M, Alvarez V.

Eur J Neurol. 2006 Apr;13(4):391-4.

PMID:
16643318
47.

Lrrk2 pathogenic substitutions in Parkinson's disease.

Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ.

Neurogenetics. 2005 Dec;6(4):171-7. Epub 2005 Sep 17.

PMID:
16172858
48.

LRRK2 mutations in Parkinson disease.

Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM.

Neurology. 2005 Sep 13;65(5):738-40.

PMID:
16157908
49.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J.

Parkinsonism Relat Disord. 2005 Sep;11(6):349-52.

PMID:
16102999
50.

LRRK2 R1441G in Spanish patients with Parkinson's disease.

Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V.

Neurosci Lett. 2005 Jul 15;382(3):309-11. Epub 2005 Apr 13.

PMID:
15925109

Supplemental Content

Loading ...
Support Center